



FOR IMMEDIATE RELEASE

EEVIA HEALTH OY PREPARES TO INCREASE ELDERBERRY EXTRACT PRODUCTION

Eevia Health Oy, a Finnish producer of organic-certified plant extracts, has received large orders from US customers for Elderberry extract, which is very popular as an immune-stimulant among other indications.

Seinäjoki, Finland, June 1st, 2020 - Eevia Health Oy produces standardized plant extracts from plant raw materials, especially berries such as lingonberries, bilberries, and other plant and fungi-material such as pine bark and Chaga mushroom. So far, all of Eevia's plant materials have been hand-picked from the pristine Arctic forests in Finnish Lapland. Recently, there has been a robust increase in demand for elderberry extracts, which grow quite widely in Europe. Eevia Health Oy has accepted to cater to this demand and has received significant orders for its new elderberry product Feno-Samucus 14. Only one single order was for 820 000 euros. However, the overall order-volume for Elderberries currently is over 2 million euros. The challenge being addressed right now is to acquire enough raw materials to serve all orders, so Eevia Health Oy cannot currently confirm for the total order demand.

"We have spent years specializing with the arctic bilberries and more typical species in the north and look forward to adding our talents to the robust elderberry market. We extracted for the same bioactive in elderberries, the anthocyanins, as we do in bilberries. It is, therefore, a very straight forward business for us to undertake this new product. We have demand for extracts from elderberry for several million euros and we have temporarily accepted only a smaller fraction of these orders while we work to increase our production. We believe that the elderberry carries the potential to be another backbone to our business, joining the lingonberry, bilberry, and other berry extracts," reveals **Sales Manager, Anna-Maija Vanhatalo** from Eevia Health Oy.

ABOUT EEVIA HEALTH OY

Eevia Health Oy, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant material from the pristine Finnish forests above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands. The focus is on ingredients that protect human health prophylactically, meaning they work to reduce the risk of developing a disease. In its portfolio, Eevia Health has immune-modulating products that have effects on Th1-type cytokines, such as IFN- γ and TNF- α cell signaling molecules, which are very important in the immune response to pathogens (virus, bacteria). Similarly, Eevia Health is developing a new product that prevents protein accumulation in the RPE-cells in the Retina, which may reduce the risk of developing eye disease AMD (Age-Related Macular Degeneration).

Eevia Health is a small, but fast-growing Finnish manufacturer of 100% organically certified plant extracts. All raw materials, such as lingonberry, bilberry, Chaga-mushroom, and pine bark, are grown in the wild and hand-picked in a sustainable fashion. The safe and effective ingredients of high quality, such as high concentrate bilberry anthocyanin extracts (36%) and pine bark extracts, are sold globally as ingredients to dietary supplement and food applications. Eevia Health operates a modern green-chemistry production facility in Finland, located close to the raw material forest source in Finnish Lapland. The short value-chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.

For additional information, please contact:

Stein Ulve, CEO
Eevia Health Oy
Mobile: +358 400 22 5967
Email: stein.ulve@eeviahealth.com

Fred Ramberg, Chairman of the Board
Eevia Health Oy
Mobile: +358 500 46 0944
Email: rambergfred@gmail.com